Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy

医学 阿哌沙班 冲程(发动机) 心房颤动 心脏病学 随机对照试验 随机化 内科学 左心房扩大 阿司匹林 华法林 拜瑞妥 机械工程 工程类 窦性心律
作者
Hooman Kamel,Will T. Longstreth,David Tirschwell,Richard A. Kronmal,Randolph S. Marshall,Joseph P. Broderick,Rebeca Aragón García,Pamela Plummer,Noor Sabagha,Qi Pauls,Christy N. Cassarly,Catherine R. Dillon,Marco R. Di Tullio,Eldad A. Hod,Elsayed Z. Soliman,David J. Gladstone,Jeff S. Healey,Mukul Sharma,Seemant Chaturvedi,L. Scott Janis
出处
期刊:JAMA [American Medical Association]
卷期号:331 (7): 573-573 被引量:234
标识
DOI:10.1001/jama.2023.27188
摘要

Importance: Atrial cardiopathy is associated with stroke in the absence of clinically apparent atrial fibrillation. It is unknown whether anticoagulation, which has proven benefit in atrial fibrillation, prevents stroke in patients with atrial cardiopathy and no atrial fibrillation. Objective: To compare anticoagulation vs antiplatelet therapy for secondary stroke prevention in patients with cryptogenic stroke and evidence of atrial cardiopathy. Design, Setting, and Participants: Multicenter, double-blind, phase 3 randomized clinical trial of 1015 participants with cryptogenic stroke and evidence of atrial cardiopathy, defined as P-wave terminal force greater than 5000 μV × ms in electrocardiogram lead V1, serum N-terminal pro-B-type natriuretic peptide level greater than 250 pg/mL, or left atrial diameter index of 3 cm/m2 or greater on echocardiogram. Participants had no evidence of atrial fibrillation at the time of randomization. Enrollment and follow-up occurred from February 1, 2018, through February 28, 2023, at 185 sites in the National Institutes of Health StrokeNet and the Canadian Stroke Consortium. Interventions: Apixaban, 5 mg or 2.5 mg, twice daily (n = 507) vs aspirin, 81 mg, once daily (n = 508). Main Outcomes and Measures: The primary efficacy outcome in a time-to-event analysis was recurrent stroke. All participants, including those diagnosed with atrial fibrillation after randomization, were analyzed according to the groups to which they were randomized. The primary safety outcomes were symptomatic intracranial hemorrhage and other major hemorrhage. Results: With 1015 of the target 1100 participants enrolled and mean follow-up of 1.8 years, the trial was stopped for futility after a planned interim analysis. The mean (SD) age of participants was 68.0 (11.0) years, 54.3% were female, and 87.5% completed the full duration of follow-up. Recurrent stroke occurred in 40 patients in the apixaban group (annualized rate, 4.4%) and 40 patients in the aspirin group (annualized rate, 4.4%) (hazard ratio, 1.00 [95% CI, 0.64-1.55]). Symptomatic intracranial hemorrhage occurred in 0 patients taking apixaban and 7 patients taking aspirin (annualized rate, 1.1%). Other major hemorrhages occurred in 5 patients taking apixaban (annualized rate, 0.7%) and 5 patients taking aspirin (annualized rate, 0.8%) (hazard ratio, 1.02 [95% CI, 0.29-3.52]). Conclusions and Relevance: In patients with cryptogenic stroke and evidence of atrial cardiopathy without atrial fibrillation, apixaban did not significantly reduce recurrent stroke risk compared with aspirin. Trial Registration: ClinicalTrials.gov Identifier: NCT03192215.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
夏目发布了新的文献求助10
1秒前
lzq发布了新的文献求助10
2秒前
英姑的应助被珍妮采纳,获得10
2秒前
托马斯之夫完成签到,获得积分10
3秒前
3秒前
活泼大象完成签到,获得积分10
3秒前
HHHZL完成签到,获得积分10
4秒前
4秒前
lurongjun完成签到,获得积分10
4秒前
Eden完成签到 ,获得积分10
5秒前
深情安青的应助被cl采纳,获得10
5秒前
温暖砖头发布了新的文献求助10
5秒前
want完成签到,获得积分10
5秒前
奔跑的应助被自豪的樱桃采纳,获得30
6秒前
mimi发布了新的文献求助10
7秒前
7秒前
8秒前
9秒前
jun发布了新的文献求助10
9秒前
horse82完成签到,获得积分10
9秒前
9秒前
bkagyin的应助被叫你吃布丁采纳,获得10
10秒前
sheryy发布了新的文献求助30
11秒前
liujx完成签到,获得积分20
11秒前
11秒前
托马斯完成签到,获得积分10
11秒前
Helen完成签到,获得积分10
11秒前
兔兔完成签到 ,获得积分10
11秒前
思源的应助被坚定的问芙采纳,获得10
11秒前
一颗士多啤梨完成签到 ,获得积分10
11秒前
康康完成签到 ,获得积分10
12秒前
上官若男的应助被内向迎蕾采纳,获得10
13秒前
13秒前
15秒前
珍妮完成签到,获得积分10
15秒前
天涯是我完成签到,获得积分10
15秒前
ding的应助被牧百川采纳,获得10
16秒前
lzq完成签到,获得积分10
16秒前
成就嚓茶完成签到,获得积分10
16秒前
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183730
求助须知:如何正确求助?哪些是违规求助? 9572975
关于积分的说明 21828453
捐赠科研通 7780887
什么是DOI,文献DOI怎么找? 3434086
关于科研通互助平台的介绍 2558276
邀请新用户注册赠送积分活动 2480557